Recent 8-K filings for CYTK

• May 8, 2026, 7:59 PM ET other material materiality 0.80 neutral item 8.01item 9.01

  Cytokinetics prices $760M public offering of 11.34M shares at $71/sh

  Offering of 9,859,155 shares at $71.00 per share; underwriters' option for 1,478,873 shares exercised in full.

• May 5, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints

  MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).

• February 24, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M

  Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).

• February 17, 2026, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

  Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

  European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.

• December 19, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

  Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM

  FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

• December 12, 2025, 6:59 PM ET regulatory materiality 0.80 positive item 8.01

  CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM

  CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes

  Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.

• September 22, 2025, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 3.02item 8.01item 9.01

  Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes

  Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.

• September 16, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01

  Cytokinetics provides FDA/EMA update on aficamten; plans to draw $100M Royalty Pharma loan

  FDA Late Cycle Meeting held; discussed REMS and label for aficamten in oHCM; PDUFA date remains Dec 26, 2025.

• September 8, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Cytokinetics presents positive aficamten data at ESC 2025; PDUFA Dec 26, 2025

  MAPLE-HCM: aficamten improved cardiac structure/function vs metoprolol (p<0.001 for diastolic function, SAM reduction); published in JACC.

• September 3, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Cytokinetics presents new aficamten data at ESC 2025; shows improvement vs metoprolol

  MAPLE-HCM: aficamten superior to metoprolol on diastolic function, SAM, and LVOT obstruction (p<0.001); reduced max wall thickness (-1.01mm, p=0.015).

• September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Aficamten superior to metoprolol in MAPLE-HCM Phase 3 trial; primary endpoint met (p<0.0001)

  Least-squares mean pVO2 difference: +2.3 mL/kg/min (95% CI 1.5 to 3.1; p<0.0001) favoring aficamten.

• August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025

  Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.

• May 6, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025

  Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.

• March 10, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 7.01

  Cytokinetics: FDA won't hold adcom for aficamten NDA; Late Cycle meeting set for June 2025

  Cytokinetics completed midcycle review with FDA for aficamten NDA treating obstructive hypertrophic cardiomyopathy.

• February 27, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025

  Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.

• November 19, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01

  Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones

  Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Cytokinetics Q2 net loss widens to $1.31/share; cash rises to $1.4B on $563M offering and $250M Royalty Pharma deal

  Net loss of $143.3M ($1.31/share) vs $128.6M ($1.34/share) in Q2 2023; revenue down to $0.2M from $0.9M.

• June 7, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01

  Cytokinetics raises ~$75M from underwriters' full exercise of overallotment option

  Underwriters purchased 1,470,588 additional shares at $51.00 per share on June 7, 2024.

• May 28, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Cytokinetics closes $500M public equity offering; concurrent $50M private placement

  Closed public offering of 9,803,922 shares at $51.00; gross proceeds ~$500M.

• May 22, 2024, 7:59 PM ET other material materiality 0.80 neutral item 1.01item 2.01item 2.03

  Cytokinetics secures $200M immediate funding from Royalty Pharma; restructures aficamten royalty

  Received $50M upfront from Tranche 6 term loan and $100M from 2024 DFA; plus $50M from CK-586 RPA; total $200M immediate cash.

• May 13, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)

  All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

13 positive 0 negative 22 neutral

source · CYTK on sec.gov